The series reviews a number of cellular processes that provide cancer drug targets, including angiogenesis, cell cycle and checkpoint control, growth factor signaling, and apoptosis. It also discusses target selection based on genomics and the specific case of the Abl inhibitor Gleevec.
Eli Keshet, Shmuel A. Ben-Sasson
William G. Kaelin Jr.
Geoffrey I. Shapiro, J. Wade Harper
Brian J. Druker, Nicholas B. Lydon
Jackson B. Gibbs